Erectile dysfunction (ED) is defined as persistent inability to achieve or maintain a penile erection sufficient for satisfactory sexu-al performance. Benign prostatic hyperplasia (BPH) is often seen at advanced age like ED, and they share a common pathophysiologic mechanism. Both are major health problems that negatively affect the patients’ quality of life. As the first-line treatment, phosphodiesterase type 5 inhibitors (PDE5i) are used for ED, and alpha-blockers for BPH. The using of PDE5i in the treatment of lower urinary tract symptoms (LUTS) due to BPH, has been gaining popula-rity in recent years. Having therapeutic effects for both erectile function and LUTS, PDE5i are good candidates as a monotherapy in BPH pati-ents. In this review, the current status of PDE5i therapy for patients with LUTS due to BPH is discussed.
Key Words: Benign prostatic hyperplasia, erectile dysfunction, phosphodiesterase type 5 enzym inhibitors, prostate
Abstract
Erectile dysfunction (ED) is defined as persistent inability to achieve or maintain a penile erection sufficient for satisfactory sexu-al performance. Benign prostatic hyperplasia (BPH) is often seen at advanced age like ED, and they share a common pathophysiologic mechanism. Both are major health problems that negatively affect the patients’ quality of life. As the first-line treatment, phosphodiesterase type 5 inhibitors (PDE5i) are used for ED, and alpha-blockers for BPH. The using of PDE5i in the treatment of lower urinary tract symptoms (LUTS) due to BPH, has been gaining popula-rity in recent years. Having therapeutic effects for both erectile function and LUTS, PDE5i are good candidates as a monotherapy in BPH pati-ents. In this review, the current status of PDE5i therapy for patients with LUTS due to BPH is discussed.
Key Words: Benign prostatic hyperplasia, erectile dysfunction, phosphodiesterase type 5 enzym inhibitors, prostate